iiinova — where your digital self keeps evolving

Foundation Medicine @foundationmedicine.bsky.social · 01/10/2026

This Breast Cancer Awareness Month, we recognize the strength of the breast cancer community & the continued need for progress in research & care. Proud to support efforts to advance precision medicine and help bring more personalized options to people facing breast cancer. 🩷

000

Foundation Medicine @foundationmedicine.bsky.social · 24/09/2026

Cancer care is complex and requires a personalized, data-driven approach to enable confident care decisions. Foundation Medicine puts quality first - explore how high-quality cancer biomarker tests provide patients with accuracy and clarity. Learn more: fpgo.io/r/oa8lrK

001

Foundation Medicine @foundationmedicine.bsky.social · 17/09/2026

Foundation Medicine’s high-quality cancer #BiomarkerTests provide accurate information about a tumor’s mutations so that healthcare teams can help patients receive the #CancerTreatment that may work best for them. Explore more: spkl.io/633217Rx3Z

Quote from Greg, Lung Cancer Patient Advocate, "Having an accurate and high-quality cancer biomarker test means everything in the world." Learn more at foundationmedicine.com/qualityfirst

000

Foundation Medicine @foundationmedicine.bsky.social · 16/09/2026

Our new molecular residual disease (MRD) test offers healthcare teams ultra-sensitive MRD detection, high-specificity and accelerated results. Learn more about our MRD test: spkl.io/633297RxPT

000

Foundation Medicine @foundationmedicine.bsky.social · 12/09/2026

At #WCLC26, we're excited to highlight 2 new posters: one on the clinical impact of NGS & targeted therapy across NSCLC histologic subtypes; the other analyzing homozygous losses & outcomes w/ standard of care treatment. Hear more from our team at booth 726. Learn more: spkl.io/633257utR1

Foundation Medicine research highlights at WCLC 2026.

000

Foundation Medicine @foundationmedicine.bsky.social · 10/09/2026

Our upcoming sponsored webinar with @genomeweb.bsky.social webinar will delve into lessons learned from bringing complex biomarkers through development – from global clinical trials, CDx approval and commercial launches. Sign up today! spkl.io/633207utpi

New Webinar - Driving Complex Biomarkers from Discovery to Global Commercialization

000

Foundation Medicine @foundationmedicine.bsky.social · 08/09/2026

Join Foundation Medicine for our “Booth Talk Series” at #WCLC26. Hear from our team of experts on the latest advancements that are driving innovation in precision diagnostics and lung cancer treatment. Review the session topics below. Learn about Foundation Medicine and more: spkl.io/633237utKb

Information on Foundation Medicine Booth Talks Series at WCLC 2026

Sessions at WCLC on Sunday, September 13th for Foundation Medicine's Booth Talk Series

Sessions at WCLC on Monday, September 14th for Foundation Medicine's Booth Talk Series

000

Foundation Medicine @foundationmedicine.bsky.social · 02/09/2026

Connect with Foundation Medicine at #WCLC26! Visit us to learn about the latest advancements in CGP and NGS at booth 726. More details here: spkl.io/633207uM1G

Foundation Medicine at 2026 World Conference on Lung Cancer - September 12-15, 2026, Booth 726

000

Foundation Medicine @foundationmedicine.bsky.social · 01/09/2026

In September, we join the global effort to raise awareness for #BloodCancers, #ChildhoodCancers, #OvarianCancer and #ProstateCancer. We are proud to foster awareness, support research and help advance innovation, this month and beyond.

000

Foundation Medicine @foundationmedicine.bsky.social · 25/08/2026

High-quality cancer #BiomarkerTests provide clear answers to help inform #treatment decisions. Because Foundation Medicine puts quality first, our tests make a difference. Learn more: spkl.io/633287Oey0

000

Foundation Medicine @foundationmedicine.bsky.social · 19/08/2026

Stay up to date with the latest insights and innovations happening in #PrecisionMedicine through our series of #biopharma webinars. Hear more from our team of experts – explore more: spkl.io/63323734Cb

Visual with text directing to Foundation Medicine's webinar library for people to learn the latest in precision medicine innovation

000

Foundation Medicine @foundationmedicine.bsky.social · 13/08/2026

A #cancer #diagnosis or recurrence can make everything seem unclear. Foundation Medicine’s high-quality #BiomarkerTests identify the unique mutations behind a patient’s cancer to help match them with the medicine more likely to work for them. Click here for more: spkl.io/633217Mhp9

000

Foundation Medicine @foundationmedicine.bsky.social · 11/08/2026

#Research published in Clinical Cancer Research proposes circulating tumor DNA (ctDNA) tumor fraction as an actionable biomarker to help identify patients with non-small cell lung cancer (NSCLC) who may benefit from combination chemo-immunotherapy. Full study findings and more here: bit.ly/4i26e0R

010

Foundation Medicine @foundationmedicine.bsky.social · 05/08/2026

Every patient deserves the opportunity to be on an effective #medicine. Foundation Medicine’s high-quality cancer #BiomarkerTests help clarify next steps and match patients like Karen with the treatment more likely to work so they can get back to doing what they love. Learn more: spkl.io/633207zoZk

000

Foundation Medicine @foundationmedicine.bsky.social · 29/07/2026

Precision #CancerCare can only be as good as the quality and accuracy of the #BiomarkerTest used to inform treatment. Find out more about Foundation Medicine’s tests and how we put quality first: spkl.io/633277Kcwl

000

Foundation Medicine @foundationmedicine.bsky.social · 27/07/2026

#ResearchSpotlight – Research published in JCO Oncology Practice demonstrated a significant reduction in lab testing turnaround time (TAT) for Foundation Medicine’s tissue-based comprehensive genomic profiling (CGP), but no change in CGP ordering or specimen processing TAT.

100

Foundation Medicine @foundationmedicine.bsky.social · 23/07/2026

Foundation Medicine’s high-quality cancer #BiomarkerTests generate reports that can clearly distill complex information to help patients like Greg and their healthcare teams decide on the #treatment plan more likely to work for them. Explore more: bit.ly/4vNMCB1

000

Foundation Medicine @foundationmedicine.bsky.social · 20/07/2026

Not all biomarker tests are created equal, impacting the accuracy, reliability and clarity of information these tests provide. Foundation Medicine’s high-quality cancer #BiomarkerTests can help inform a personalized treatment plan for patients with #cancer. Learn more: spkl.io/633237y7l5

010

Foundation Medicine @foundationmedicine.bsky.social · 16/07/2026

Excited to announce the launch of our new campaign: Quality First. High-quality cancer #BiomarkerTests uncover the specific mutations behind a patient’s #cancer and provide personalized treatment options more likely to work for them, rather than a “one-size-fits-all” approach.

110

Foundation Medicine @foundationmedicine.bsky.social · 13/07/2026

Foundation Medicine will be at the Liquid Biopsy for Precision Oncology Summit East Coast! We’re looking forward to connecting with industry leaders and discussing the latest innovations in liquid biopsy development, including advancements in MRD detection.

110

Foundation Medicine @foundationmedicine.bsky.social · 07/07/2026

Our latest Genomics in Moments video dives into Quantity Not Sufficient (QNS). #DYK limited tissue doesn’t have to limit genomic insights that can help inform treatment decisions? Watch to learn more.

000

Foundation Medicine @foundationmedicine.bsky.social · 30/06/2026

We’re looking forward to joining researchers and oncology leaders at #ESMOGI26 in Munich. Our research at the meeting includes a new poster on the impact of liquid biopsy comprehensive genomic profiling on time to treatment initiation in #GI #cancers.

100

Foundation Medicine @foundationmedicine.bsky.social · 26/06/2026

Connect with Foundation Medicine at #ESMOGI26! Visit us to learn about the latest advancements in comprehensive genomic profiling at Booth 23. More details here: spkl.io/6332571VVV

Foundation Medicine at ESMO Gastrointestinal Cancers Congress 2026, July 1-4

000

Foundation Medicine @foundationmedicine.bsky.social · 26/06/2026

#Research from the team published in JCO Precision Oncology analyzed the genomics of MTAP loss in over 500,000 solid tumor specimens. Click through below for more information and key findings. Explore the full publication here: bit.ly/4vxRafD

000

Foundation Medicine @foundationmedicine.bsky.social · 12/06/2026

@genomeweb.bsky.social recently sat down with Foundation Medicine on the launch of our newest test, FoundationOne®MRD. Read more: spkl.io/633257D6Xb *FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA

spkl.io

Foundation Medicine Rebrands Saga Diagnostics MRD Test, Seeks New Indications

Roche purchased Saga Diagnostics earlier this year in a $595 million transaction and integrated the company into its Foundation Medicine subsidiary.

000

Foundation Medicine @foundationmedicine.bsky.social · 09/06/2026

We look forward to attending #EHA2026 and connecting with the global hematology community. Heading to Stockholm? Visit us at booth G1.01 (Hall C) - reach out to our team to learn more: spkl.io/633257B0Ud

Foundation Medicine at EHA2026 - June 11-14, Stockholm, Sweden

020

Foundation Medicine @foundationmedicine.bsky.social · 08/06/2026

#Research demonstrated the clinical validation of ctDNA tumor fraction dynamics as a prognostic biomarker in patients with mTNBC receiving chemo with or without immunotherapy. Results also showcased the value of serial ctDNA monitoring in patients who are responding to treatment: spkl.io/633227B0Wo

Research Spotlight - Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial

Background on research spotlight for the publication "Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial"

Key findings on research spotlight for the publication "Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial"

000

Foundation Medicine @foundationmedicine.bsky.social · 04/06/2026

#ASCO26 has come to an end and our team is looking back at our time in Chicago last weekend! Thank you to all who stopped by our booth and connected with our team. #WeAreFMI

000

Foundation Medicine @foundationmedicine.bsky.social · 03/06/2026

Proud to introduce FoundationOne®MRD,* the first-of-its-kind molecular residual disease test to combine structural variants and digital PCR. *FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.

100

Foundation Medicine @foundationmedicine.bsky.social · 02/06/2026

New companion diagnostic announcement - our tissue-based comprehensive genomic profiling (CGP) test has been FDA-approved to identify patients with hormone receptor-positive, HER2-negative #BreastCancer with a PIK3CA mutation for a targeted therapy combination.

100

Foundation Medicine @foundationmedicine.bsky.social · 01/06/2026

Interested in how Foundation Medicine’s new molecular residual disease assay* can support your clinical trials? Register for our webinar: event.on24.com/wcc/r/536220... *FoundationOne®MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.

100

Foundation Medicine @foundationmedicine.bsky.social · 01/06/2026

Companion Diagnostic Approval - our tissue and blood-based comprehensive genomic profiling (CGP) tests have been approved by the FDA as companion diagnostics for a combination therapy to identify patients w/ HRR gene-mutated mCRPC: bit.ly/4amufuW

100

Foundation Medicine @foundationmedicine.bsky.social · 31/05/2026

#ASCO26 - Results reported from the experimental arm of the phase II COPE trial provide insights on the impact of serial ctDNA genomic profiling for treatment guidance and outcomes for patients with non-small cell lung cancer. Visit us at booth 19145: spkl.io/6332076bIO

Research highlights from Foundation Medicine at #ASCO26 include results reported from the experimental arm of the phase II COPE trial that provide insights on the impact of serial circulating tumor DNA genomic profiling for treatment guidance and outcomes for patients with non-small cell lung cancer.

000

Foundation Medicine @foundationmedicine.bsky.social · 30/05/2026

Utilizing real-world genomic data, two new pieces of #research being presented at #ASCO26 explore the prevalence & co-occurrence patterns of HRDsig status in two disease areas: advanced breast cancer & advanced gallbladder adenocarcinoma. Meet w/ our team: spkl.io/6332876vwo

Research highlights from Foundation Medicine at #ASCO26 include two new pieces of research that explore the prevalence and co-occurrence patterns of a homologous recombination deficiency signature (HRDsig) status in two disease areas: advanced breast cancer and advanced gallbladder adenocarcinoma.

010

Foundation Medicine @foundationmedicine.bsky.social · 29/05/2026

We're thrilled to announce the launch of our FoundationOne®MRD* tumor-informed molecular residual disease test. Read more: spkl.io/6332576Qhh *FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA

Foundation Medicine Launches FoundationOne®MRD*, a tumor-informed molecular residual disease test

FoundationOne MRD is the first-of-its-kind molecular residual disease test to combine structural variants and digital PCR

FoundationOne MRD provides accelerated results, with the personalized tumor baseline and initial blood test expected within approximately 2 to 3 weeks from the sample receipt, and subsequent blood test results anticipated within 1 to 3 days.

FoundationOne MRD is covered by Medicare for cancer recurrence monitoring in early-stage breast cancer across all subtypes

012

Foundation Medicine @foundationmedicine.bsky.social · 29/05/2026

Updates in #RareCancer research: New insights from the TRACK study found that comprehensive genomic profiling identified pathogenic alterations in nearly all rare cancer patients, w/ tissue-agnostic, actionable biomarkers seen in 9% of tumor types. Meet w/ us at #ASCO26, booth 19145: bit.ly/4af2Lau

Research highlights from Foundation Medicine at #ASCO26 include updates in rare cancer research such as new insights from the TRACK study found that comprehensive genomic profiling identified pathogenic alterations in nearly all rare cancer patients, with tissue-agnostic, actionable biomarkers seen in 9% of tumor types.

000

Foundation Medicine @foundationmedicine.bsky.social · 28/05/2026

#ResearchHighlights from Foundation Medicine at #ASCO26: copy number loss. Two studies will provide insights on common homozygous gene losses in head and neck cancer and the ability of liquid biopsy CGP to detect MTAP loss.

110

Foundation Medicine @foundationmedicine.bsky.social · 28/05/2026

We are excited to launch advanced digital solutions for healthcare providers through an integration with navify® Clinical Hub, including AI-powered clinical trial matching, publication search, patient education materials and digitized guideline mapping.

100

Foundation Medicine @foundationmedicine.bsky.social · 27/05/2026

A recent publication explored the key role of biomarker testing utilizing Foundation Medicine’s tissue-based comprehensive genomic profiling assay. Results showcase the importance of CGP testing to identify actionable biomarkers across all subtypes of non-small cell lung cancer.

100

Foundation Medicine @foundationmedicine.bsky.social · 22/05/2026

New insights on copy number loss detection, circulating tumor DNA (ctDNA) genomic profiling, our proprietary homologous recombination deficiency signature (HRDsig) & more at #ASCO26. Explore our research being presented: www.foundationmedicine.com/press-releas...

010

Foundation Medicine @foundationmedicine.bsky.social · 21/05/2026

Excited to announce that our tissue-based comprehensive genomic profiling (CGP) test has been approved by the FDA as a companion diagnostic for another targeted therapy to identify patients with MET Exon 14 skipping alterations in NSCLC: www.foundationmedicine.com/press-releas...

100

Foundation Medicine @foundationmedicine.bsky.social · 20/05/2026

Our research published in Clinical Cancer Research introduces Foundation Medicine’s research use only AmpRatio biomarker, an NGS-based approach that precisely measures the magnitude of gene amplification by accounting for tumor ploidy. Scroll through to explore more insights.

100

Foundation Medicine @foundationmedicine.bsky.social · 19/05/2026

We’re excited to join @statnews.com again this year at the STAT@ASCO: Science vs. Cancer event as the presenting sponsor, featuring a session with our CEO Dan Malarek. Going to be in Chicago? Join us: spkl.io/63324AhDbr

spkl.io

STAT@ASCO: Science vs. Cancer

STAT returns to Chicago for its annual event alongside ASCO, the largest cancer research conference in the world.

010

Foundation Medicine @foundationmedicine.bsky.social · 14/05/2026

We are excited to provide a pharmacogenetic offering along w/ our portfolio of high-quality comprehensive genomic profiling tests. This new test can help healthcare providers gain a deeper understanding to help guide cancer therapy selection & support more effective patient care.

100

Foundation Medicine @foundationmedicine.bsky.social · 13/05/2026

Foundation Medicine is heading to Chicago for #ASCO26! We’re excited to showcase our latest research, high-quality testing portfolio and our biopharma services and capabilities. Our team would love to meet with you, schedule time today: spkl.io/63322ACJXr

Foundation Medicine at #ASCO26 - May 29-June 2, 2026. Booth 19145.

000

Foundation Medicine @foundationmedicine.bsky.social · 06/05/2026

#DYK MTAP loss is a highly prevalent alteration actively being targeted in clinical trials, but its complexity can derail programs if not addressed early. Hear more about peer-reviewed data & see how biomarker decisions can impact clinical trials. Sign up: spkl.io/63329A784t

Upcoming Webinar - Don't Miss the Signal: Detect MTAP Loss More Often in Your Clinical Trials. May 20, 2026 - 12:00 PM ET

000

Foundation Medicine @foundationmedicine.bsky.social · 05/05/2026

This month, we’re helping shine a light on the importance of #SkinCancer and #Melanoma awareness. By encouraging sun-safe habits and greater education, we can help spread more information about the signs and risks.

Recognzing Melanoma & Skin Cancer Awareness Month

010

Foundation Medicine @foundationmedicine.bsky.social · 04/05/2026

Through our partnership with Fulgent Genetics, our new offering helps identify genetic differences that can influence how medicines are metabolized and processed by the body, including genes such as DPYD. Explore more about our latest product: www.foundationmedicine.com/press-releas...

000

Foundation Medicine @foundationmedicine.bsky.social · 25/04/2026

🧬 Today we recognize DNA Day and the impact of genomics in science, medicine and patient care. We are proud to play a role in all the progress happening today and look forward to continuing to help drive advancements in precision medicine.

000

Foundation Medicine @foundationmedicine.bsky.social · 23/04/2026

#Research published in @natcomms.nature.com highlights the potential utility of circulating tumor DNA (ctDNA) monitoring for informing early treatment response in patients with advanced breast cancer.

100